Rockwell Medical (NASDAQ:RMTI) executives told investors that 2025 was a “defining year” marked by shifts in the company’s customer base and purchasing volumes, alongside operational changes aimed at stabilizing demand and improving profitability. On the company’s fourth-quarter and full-year 2025 earnings call, management highlighted expanding gross margins late in the year, positive fourth-quarter operating cash flow, and a higher year-end cash balance, while also acknowledging that full-year revenue declined due to reduced purchasing from a customer.
Customer mix shifts and contract updates
President and CEO Dr. Mark Strobeck said Rockwell’s strategy has been focused on building a more durable business by reducing customer concentration risk and improving revenue stability. He said Rockwell now serves approximately 300 customers in the U.S., including all five leading dialysis providers, and supplies hemodialysis concentrates to more than 30 countries.
- Fresenius: Strobeck said Rockwell supplied Fresenius consistently through 2025 under an agreement signed in 2024, and based on Fresenius projections, Rockwell expects that business to grow in 2026.
- DaVita: Strobeck said DaVita had intended to transition away from Rockwell by mid-2025 but did not, extending the agreement through the end of 2026 with increased product pricing. In Q&A, he said DaVita has provided a 2026 forecast and is purchasing at volumes “consistent with and slightly above” projections.
- Innovative Renal Care (IRC): The company signed a multi-year, multi-million-dollar agreement with utilization commitments for three years, with an option for an additional year. Strobeck said Rockwell now supplies 70% of IRC clinics.
- Dialysis Clinic, Inc. (DCI): Rockwell remains under a long-term agreement supplying and delivering to over 80% of DCI clinics.
- Concerto Renal Services: Rockwell signed a three-year purchase agreement with a one-year renewal option, including supply and purchasing minimums for liquid and dry acid bicarbonate concentrates and bicarbonate cartridges. Management said Rockwell supplies 100% of facilities where Concerto provides dialysis services.
West Coast disruption creates new foothold
Strobeck said a hemodialysis concentrate supplier in the western U.S. wound down operations due to regulatory and compliance-related concerns, creating a supply chain disruption. Rockwell said it responded by rapidly scaling production and expanding logistics to meet demand, adding 30 new customers in the West.
During Q&A, management said it is working to put those customers under long-term agreements and is developing a commercial strategy to expand further in the region. Strobeck also referenced Rockwell’s partnership with B. Braun, saying B. Braun is “heavily focused in the West” and that combined efforts could help target additional dialysis centers.
Product portfolio: bicarbonate cartridges and at-home dialysis
Rockwell said it diversified its hemodialysis concentrate portfolio by adding a single-use bicarbonate cartridge that is FDA 510(k) cleared and available in 720-gram and 900-gram sizes. Strobeck said interest in the disposable cartridge has been rising among existing and prospective customers, and the company expects to generate about $1 million in net sales from bicarbonate cartridges in 2026.
Asked about at-home dialysis, Strobeck said the at-home segment is “probably trending towards what will be about 10%” of the overall dialysis and hemodialysis market. He said Rockwell works with some of the largest players in that space and believes the company is positioned to benefit as the market grows, noting Rockwell has product configurations that work well in the home setting.
Operational changes and margin expansion
Management attributed margin expansion—especially in the fourth quarter—to structural operational improvements rather than one-time actions. Strobeck cited tighter pricing discipline across a more diversified customer base, operational efficiencies that reduced costs and improved throughput, and a more stable production and logistics environment that improved planning.
In the fourth quarter, Rockwell appointed Rashad Brown as vice president of manufacturing and supply chain. Strobeck said Brown has experience in regulated manufacturing environments, including prior work at Fresenius, and that his leadership is already improving execution and operational discipline. Management said it expects further manufacturing efficiency gains in 2026 and beyond.
Financial results: lower sales, higher Q4 margin, improved cash
CFO Jesse Neri said Rockwell focuses on three key metrics—cash, gross margin, and adjusted EBITDA—to assess progress in aligning its cost structure to changes in the customer base. He highlighted that cash increased from $17.3 million at the end of March 2025 to $25.0 million at year-end, gross margin rose from 16% in the first quarter to 21% in the fourth quarter, and adjusted EBITDA improved each quarter from negative $400,000 in the first quarter to positive $1.0 million in the fourth quarter.
For the fourth quarter of 2025, Rockwell reported:
- Net sales: $18.3 million, up 15% from Q3 2025 but down 26% from Q4 2024. Neri said the year-over-year decrease reflected an expected reduction in purchase volumes by one customer.
- Gross profit: $3.9 million, up 70% from Q3 2025 and in line with Q4 2024.
- Gross margin: 21%, up from 14% in Q3 2025 and 15% in Q4 2024; management described it as one of the strongest quarterly gross margin results in company history.
- Net loss: $600,000, improving from a $1.8 million net loss in Q3 2025 and slightly better than the $800,000 net loss in Q4 2024.
- Adjusted EBITDA: positive $1.0 million, up $900,000 sequentially and generally in line with Q4 2024.
For the full year 2025, Rockwell reported net sales of $69.3 million, down 32% from $101.5 million in 2024, and gross profit of $11.7 million, down from $17.5 million. Full-year gross margin was 17%, which management said was in line with both annual guidance and 2024. Full-year net loss was $5.3 million versus a $500,000 net loss in 2024; Neri said the 2025 net loss included $4.0 million of non-cash depreciation, amortization, and stock compensation, as well as $1.2 million of severance and other restructuring costs tied to facility transitions. Full-year adjusted EBITDA was positive $300,000, compared to positive $5.0 million in 2024.
Neri said Rockwell generated positive operating cash flow of $2.3 million in the fourth quarter, partially offset by cash paid related to the Evoqua asset acquisition. Cash, cash equivalents, and investments available for sale totaled $25.0 million at year-end 2025, up $1.3 million from the end of the third quarter.
Looking ahead, Rockwell guided to 2026 adjusted EBITDA of $1 million to $2 million and said it expects operating cash flow to be positive. Strobeck added that the company is in negotiations with several large customers and expects to provide guidance on net sales and gross margin “in the near future.” He also outlined longer-term goals through 2029, including a belief the company could be positioned for annual net sales above $100 million, upward-trending gross margins potentially approaching the 30% range, and annual profitability in the $5 million to $10 million range, while emphasizing these are longer-term directional views subject to risks and uncertainties.
About Rockwell Medical (NASDAQ:RMTI)
Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.
The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.
